色播婷婷电影综合社区,AV女优不卡亚洲在线,99999AV,日韩人妻中文字幕视频,国产拍自偷,91人人妻,超碰在线81,免费福利视频一区,九草青草原在线看

Chongqing Zyscin Pharmaceutical Technology Co., Ltd. was established on January 2, 2020, located in the Dadi Enterprise Park, Shuitu Industrial Park, Liangjiang New District, Chongqing, about 30 kilometers from Jiangbei International Airport and 35 kilometers from Chongqing North Railway Station, with convenient transportation. The total construction area of the company is 2000m2, with 1100m2 research and development, analysis room, 900m2 office.

The company's R & D laboratory is not only equipped with GC, HPLC and other conventional analysis and testing instruments, but also equipped with HPLC-MS, and the company's nearby cooperation units provide NMR analysis services, effectively guaranteeing research and development capabilities. In addition, the R & D laboratory is equipped with 500ml, 2000ml hydrogenation reactor and 10L, 50L glass reactor, silicon carbide micro-channel continuous reactor and tubular continuous reactor, with rich R & D and conversion capabilities.

In October 2021, the company purchase Jiangxi juhe Pharmaceutical Technology Co., Ltd. as a production base. Jiangxi juhe Pharmaceutical Technology Co., Ltd. is located in Jindui Industrial Park, Shanggao County, Yichun City, Jiangxi Province, which belongs to Jiangxi provincial chemical park, covers an area of 40,000 square meters, has 4 production workshops, 2 workshops have been put into use. The production base has complete supporting facilities, complete wastewater and waste gas treatment facilities, independent EHS department and quality assurance department (QA), and has passed the EHS and quality system audit of domestic and foreign pharmaceutical company.

The company has a team of high-quality professionals, composed of management, research and development, production technology team, with the background of working and communicating with middle and senior personnel of big foreign pharmer companies such as Pfizer, Roche, Janssen, Belgium, and has a set of perfect experience in the research and development, production and management of new drugs in China.

In addition to the research and development and production of new drugs such as cardiovascular drugs, antiviral drugs and anti-tumor drugs, the company also undertakes CRO, CDMO and CMO business.